ALLO Stock — Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (ALLO)

Updated October 16, 2026.

ALLO is a Stock. Total return is -94.8% over the past 8 years, 310.9 points behind SPY at 216.1%.

Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies to treat cancer and autoimmune diseases, with a pipeline including candidates targeting CD19 for large B-cell lymphoma, CD70 for renal cell carcinoma, and both CD19 and CD70 for conditions such as systemic lupus erythematosus. The company does not currently distribute to shareholders. As a pre-commercial biotechnology firm, it appeals primarily to investors with a high risk tolerance for early-stage drug development and a focus on long-term capital appreciation rather than current income.

ALLO performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.8% over the past 8 years, 310.9 points behind SPY at 216.1%. Over the past year its total return — price change plus distributions reinvested — is 3.2%. Its deepest 1-year drawdown was 57.8%.

ALLO key facts

Asset type

Stock

Asset class

Equity

Inception date

10/11/2018

Distribution frequency

None

Last close

$1.31 (as of 2026-10-16)

Market cap

$452,593,054

Average volume

4918663.0

Beta

0.559

Payout ratio

0.0%

EPS

$-0.66

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ALLO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.8%.

Who may consider ALLO — and who may not

It is a weaker fit for investors who need monthly cash flow (ALLO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ALLO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions